Cell and gene therapy answers: Overcoming challenges for rare disease in pediatrics

Your source for answers to the complex challenges of cell and gene therapy development.

Three healthy habits to fight cardiovascular disease

February is American Heart Month and, perhaps more famously, home to Valentine’s Day. This makes it an ideal time for you to start loving your heart.

Improving diagnostic efficiencies in histology with artificial intelligence and digital scoring

Digital analysis and artificial intelligence (AI) are not novel in anatomic pathology and histology, but the technology continues to evolve as it supports clinical trial enrollment as well as routine work in pathology.

Optimizing success in application for US EPA registration of conventional new plant protection active substances under FIFRA

To open up the US crop protection market for an active substance you have already registered elsewhere, you will need to compare your existing data against the regulatory requirements of the US Environmental Protection Agency (EPA). In this blog, we outline the US regulatory landscape and suggest ways of optimizing registration success within it.

Rare Disease Day 2022: Supporting patients, celebrating advancements

February 28 is Rare Disease Day, a day dear to the hearts of many at Labcorp. The day is observed to raise awareness and give support to the more than 300 million people worldwide living with rare diseases, as well as their family members and caretakers.

TSCA and US state legislation: Navigating your chemical or agrochemical through the federal and state regulatory landscape in the USA

Registering your chemical or crop protection product with the US EPA under TSCA or FIFRA is the first and biggest step in its regulatory journey in the USA. But you will also need to navigate state-specific legislation and regulations, and for crop chemicals this includes registering in every state where they will be used.

Advancing inhalation toxicology capabilities to support chemical testing

Respiratory exposure to chemicals or agrochemicals poses potential risk to human health, especially to workers handling these products. Whether preparing a solution, dusting or spraying crops, or cleaning equipment, opportunities for inadvertent inhalation is a risk that can potentially lead to toxic effects, both acute and chronic. That’s why identifying potential risk posed by respiratory exposure to a chemical or agrochemical is a mandatory component of toxicology studies in regulatory submissions for new registrations and, often, for re-registrations. In addition to the requirement, inhalation studies themselves are complex and challenging, as delivery of test articles via the inhalation route requires careful attention to substance aerosolization and particle size as well as constant control and monitoring over a prolonged time.

Labcorp Patient Access Solutions Asembia discussions for 2022

At industry events, there are the discussions you hear inside of sessions, and there are also the discussions that take place outside of sessions. During the October 2021 Asembia event, we heard several common themes among attendees, clients, prospects and vendors

Cell & Gene Therapy Answers: Preclinical Oncology

As the landscape of cell therapy continues to evolve, so are the tools to assess the efficacy of cell therapy in the preclinical space. To better understand Labcorp’s preclinical oncology role in cell therapy development, we spoke with Sheri Barnes, associate director of scientific development for Labcorp preclinical oncology, who assists drug development sponsors in study design and model selection for preclinical oncology studies, along with David Draper, associate director of scientific development for Labcorp preclinical oncology who helps sponsors understand how in vitro services can be used effectively to address their preclinical investigational needs.

Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry

A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to have the ability to detect and quantify these malignant cells.